Mould breakthrough in immunosuppressed adults receiving anidulafungin: A report of 2 cases

Journal of Infection

Volumn 55, Issue 5, 2007, Pages

  Wetzstein, Gene A ^a   Green, Myke R ^a   Greene, John N ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Anidulafungin; Breakthrough; Immunosuppressed; Mould; Resistance

Indexed keywords

ACICLOVIR; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; FLUDARABINE; LEVOFLOXACIN; METHYLPREDNISOLONE; MICAFUNGIN; PENTOSTATIN; POSACONAZOLE; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; ASPERGILLUS FUMIGATUS; CANCER CHEMOTHERAPY; CASE REPORT; DEATH; DRUG MEGADOSE; DRUG SUBSTITUTION; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERBILIRUBINEMIA; LIVER FUNCTION TEST; LUNG LAVAGE; MALE; MANTLE CELL LYMPHOMA; MOULD; MYCOSIS; MYELODYSPLASIA; NEUTROPENIA; PNEUMONIA; SEPSIS; SIDE EFFECT; WHOLE BODY RADIATION;

ADULT; AGED; ANTIFUNGAL AGENTS; ECHINOCANDINS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; MYCOSES; SUPERINFECTION;

EID: 35348960344     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2007.08.003     Document Type: Article

References (9)

1. Pfaller M.A., Pappas P.G., and Wingar J.R. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 43 Suppl. 1 (2006) S3-S14
2. Cappelletty D., and Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 27 3 (2007) 369-388
3. List A.F., Kopecky K.J., Willman C.L., Head D.R., Persons D.L., Slovak M.L., et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98 12 (2001 Dec 1) 3212-3220
4. Perlin D.S. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat (2007 Jun 12) [Epub ahead of print]
5. Miller C.D., Lomaestro B.W., Park S., and Perlin D.S. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 26 6 (2006 Jun) 877-880
6. Laverdiere M., Lalonde R.G., Baril J.G., Sheppard D.C., Park S., and Perlin D.S. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 57 4 (2006 Apr) 705-708
7. Kuse E.R., Chetchotisakd P., da Cunha C.A., Ruhnke M., Barrios C., Raghunadharao D., et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369 9572 (2007 May 5) 1519-1527
8. Yanada M., Kiyoi H., Murata M., Suzuki M., Iwai M., Yokozawa T., et al. Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. Intern Med 45 5 (2006) 259-264
9. Pappas P.G., Rotstein C., Betts R., Nucci M., Talwar D., De Waele J.J., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45 7 (2007 October 1) 883-893